No treatment, just tracking: new study maps rare bone disease in russia

NCT ID NCT07390240

Recruiting now Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 25, 2026

Summary

This study is not testing a new drug or treatment. Instead, researchers are observing 55 children and adults in Russia who have hypophosphatasia (HPP), a rare genetic bone disease. The goal is to better understand how the disease naturally unfolds over time by tracking symptoms, lab results, and quality of life. This information could help doctors diagnose and manage HPP more effectively in the future.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOPHOSPHATASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Moscow, Russia
Research Site
RECRUITING

Rostov-on-Don, Russia
Research site
COMPLETED

Moscow, Russia
Research site
RECRUITING

Saint Petersburg, Russia

Conditions

The condition(s) this trial relates to.

hypophosphatasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPOPHOSPHATASIA